Prostate cancer patients who undergo radical prostatectomy achieve better results at teaching hospitals than at non-academic medical institutions, according to the findings of an international study led by researchers at Henry Ford Hospital?s Vattikuti Urology Institute, Detroit.
Aristolochic acid, a plant component used in herbal remedies, appears to lead to kidney failure and urothelial cell carcinomas (UCC) in individuals exposed to the toxin, an international group of researchers reports.
The U.S. Preventive Services Task Force (USPTF) announced it was no longer recommending the PSA test to screen healthy men for prostate cancer, but experts say the impact this recommendation could have on health insurance coverage and treatment decisions remains unclear. While insurers are likely to take their time issuing formal coverage decisions, the AUA and other urology organizations have been quick to respond to the recommendation.
Glenn M. Preminger, MD, has been appointed chief of urologic surgery at Duke University Medical Center, Durham, NC.
Men who take a daily vitamin E supplement face an increased risk of prostate cancer, according to a new report summarizing the latest results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
The Alliance of Specialty Medicine soundly rejected MedPAC?s approval of a recommendation that Congress reform the Medicare reimbursement system by reducing reimbursements to specialists by 5.9% per year for 3 years while freezing the reimbursement rate for primary care physicians.
Efforts in an increasing number of states to not provide Medicaid insurance coverage for male circumcision, as well as an attempted ballot initiative in San Francisco earlier this year to ban male circumcision in newborns and young boys, are unwarranted, say infectious disease experts from Johns Hopkins University, Baltimore.
Researchers at Fred Hutchinson Cancer Research Center and the University of Washington, Seattle have discovered a number of potential key drivers?recurrent genetic mistakes?common to advanced prostate cancer that may contribute to disease progression.
Men over 75 years of age are being undertreated for prostate cancer, while patients with a single comorbid condition such as peripheral vascular disease are being overtreated and doing much more poorly than expected, say researchers from UCLA?s Jonsson Comprehensive Cancer Center.
The future of patient-centered urologic care depends on collaboration with allied advocacy affiliates.
This list of National Institutes of Health trials is derived from the NIH's database and includes phase III and IV bladder cancer trials and phase II overactive bladder trials. This list is current as of Sept. 15, 2011.
Near infrared fluorescence imaging of intravenous indocyanine green during robot-assisted laparoscopic partial nephrectomy can accurately identify the renal vasculature and successfully differentiate tumor from surrounding parenchyma.
Serum testosterone concentration rises in a predictable manner after implantation of extended-release testosterone pellets (Testopel), and the dose response is not impacted by the patient's body mass index.
Accumulating data from patients with progressive, castration-resistant prostate cancer enrolled in a phase I-II study of MDV3100 show this novel antiandrogen has durable antitumor activity in both pre- and post-chemotherapy populations.
An investigational minimally invasive urethral expansion system achieved significant and durable improvement in BPH/lower urinary tract symptoms in a multicenter study.
By analyzing work relative value units (RVUs) in a number of urology groups, we have verified that they have had an approximate 10% decrease in income while generating the same number of work RVUs.
The newest urology products and services from US Urology, Cook Medical, Abbott Laboratories, the Medical Collaboration Network, the Agency for Healthcare Research and Quality, the AUA Foundation, and Trophikos, LLC.
A team at the University of Washington School of Medicine and Applied Physics Lab, Seattle, is refining prototype technology that should allow extracorporeal ultrasound to image and, more importantly, move stones in a kidney as if they were being nudged gently by a pool cue.
Those of us who are not employed by a hospital or other entity remain small business men/women, and therefore need to be as attentive to the business aspect of our practices as we are to the clinical care we offer our patients.
Repeat injections of onabotulinumtoxinA (Botox) over the long term are showing value in patients with interstitial cystitis.
The investigational selective beta3-adrenoceptor agonist mirabegron effectively improves symptoms of overactive bladder and is very safe and well tolerated.
An organization's mission is more than its day-to-day activities. Writing a new mission statement can be a refreshing opportunity to step away from the busywork and refocus on what matters most.
Our commitment to our patients must be sustained. As a result, LESS is in everyone's future in one form or another.
After seeing physicians in Maine ask legislators to delay a bill limiting medical liability, speculation is that because doctors who have joined large groups or hospital practices have fewer concerns related to running a business-eg, meeting payroll, hiring staff, malpractice premiums, and meeting overhead-their priorities might be shifting.
Robotic pyeloplasty demonstrated several operative and outcome advantages over the laparoscopic technique in patients with ureteropelvic junction (UPJ) obstruction.
Adding vibrotactile feedback to robotic minimally invasive surgery can increase awareness of tool actions and surgeons' perceived ability to concentrate.
Urologists at Cleveland Clinic have undertaken a pilot program involving modification of a commercial electronic medical record (EMR) system to facilitate clinical research and clinical practice outcomes analysis in a way that overcomes the obstacles presented by the record-keeping technology.
Urologists want Medicare to be run efficiently and be easy for patients to navigate, regardless of whether it's run by the government or private industry.
Daniel P. Petrylak, MD, explains the role of new first- and second-line prostate cancer therapies, how they address previously unmet needs, and their associated side effects.